CVA 21

Drug Profile

CVA 21

Alternative Names: Cavatak; Coxsackievirus A21; CVA-21

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator ViroTarg
  • Developer Viralytics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action CD55 antigen inhibitors; Cell death stimulants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Bladder cancer; Lung cancer; Prostate cancer
  • Suspended Head and neck cancer
  • No development reported Breast cancer; Chronic lymphocytic leukaemia; Glioma; Mesothelioma; Multiple myeloma; Pancreatic cancer

Most Recent Events

  • 05 Apr 2017 Viralytics plans a pivotal registrational clinical trial in Malignant melanoma (Combination therapy, Second-line therapy or greater)
  • 05 Apr 2017 Updated safety data from phase I KEYNOTE-200/STORM trial in Solid tumours presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 04 Apr 2017 Interim efficacy and adverse events data from the phase Ib CAPRA trial presented at the 108th Annual Meeting of the American Association of Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top